Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome
Taysha Gene Therapies Receives Breakthrough Therapy Designation (Community Letter)
Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome
Taysha Gene Therapies Updates on Part B Pivotal Study (Community Letter)
Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides CorporateUpdate
Taysha Gene Therapies Updates on Part A Data, Plans for the Part B Pivotal Study, and FAQs (Community Letter)
Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102
Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update
Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update
Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Transforming the Landscape of Rett Research
The International Rett Syndrome Foundation (IRSF) hosted its annual scientific meeting in Westminster, Colorado on June 18-19, 2024, as part of its ASCEND 2024 Rett Syndrome National Summit.